clinical-trials

Details up front: dizziness · orforglipron · SURPASS-3. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…

The specifics, since they change the answer: FLOW · 60 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am…

I have three data points across nine months, which I hope is enough to see a trend. I can parse the result. I am less sure what it licenses me to conclude. I have…

Setup, so nobody has to ask: PIONEER-1 · fatigue · 10 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full…

Setup, so nobody has to ask: FLOW · vomiting. I have read the primary source rather than the summary, which has left me with more questions. I understand the…

The label documentation for the agent in question is ambiguous on exactly this point. I have read the primary source rather than the summary, which has left me with…

Concretely: survodutide · SURMOUNT-1. I want to know whether this is a real physical effect or an artefact of how it is measured. What prompted the question is an…

Concretely: STEP 4 · tirzepatide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which…

Conditions: 10 mg · tirzepatide. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the plan to…

Setup, so nobody has to ask: constipation · mazdutide · SURMOUNT-2. I have read the primary source rather than the summary, which has left me with more questions. I…

Setup, so nobody has to ask: SUSTAIN-6 · 50 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the…

What I am working with: SOUL · a GLP-1 receptor agonist. This is asserted often enough that I assumed it was established, and then I went looking for the source. I…

Details up front: ATTAIN-1 · orforglipron. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

What I am working with: retatrutide · tirzepatide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain…

Details up front: PIONEER-1 · retatrutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence…

Numbers first: a GLP-1 receptor agonist · 25 °C. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the…

Details up front: vomiting · orforglipron · SURMOUNT-1. This is presented as though it settles something, and I am not convinced it does. I have two documents that…

The specifics, since they change the answer: STEP 3 · early satiety. I want to understand what this actually establishes, as opposed to what it is being used to…

What I have: STEP 3 · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

Details up front: mazdutide · 4 °C. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am interested…

The particulars: PIONEER-4 · survodutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

For reference: oral semaglutide · tirzepatide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for each and…

Details up front: cagrilintide · 30 °C. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…

Conditions: TRIUMPH-3 · 2 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change the…